BRAF Kinase Inhibitors Market size to grow at a CAGR of 7.73% from 2021 to 2026, Driven by the high target affinity and specificity of BRAF kinase inhibitors - Technavio

NEW YORK, April 11, 2023 /PRNewswire/ -- The BRAF kinase inhibitors market size is forecasted to increase by USD 1.19 billion from 2021 to 2026, at a CAGR of 7.73%, according to the recent market study by Technavio. The growth of the market will be driven by the high target affinity and specificity of BRAF kinase inhibitors, the presence of patient assistance programs, and the increasing prevalence of cancer. Technavio offers an up-to-date analysis of the current global market scenario and the overall market environment. View a Sample Report  

Technavio categorizes the global BRAF kinase inhibitors market Vendor Analysis:

The global BRAF kinase inhibitors market is concentrated, with a few companies and four approved drugs. Technavio has extensively analyzed 15 major vendors, including Asana BioSciences LLC, Bayer AG, BeiGene Ltd., F. Hoffmann La Roche Ltd., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., and Pierre Fabre SA

Vendor Offerings -

• Asana BioSciences LLC - The company offers BRAF Kinase inhibitors such as ASN003 and ASN007.
• Bayer AG - The company offers BRAF Kinase inhibitors such as Sorafenib through the medicine named Nexavar 200.
• BeiGene Ltd. - The company offers BRAF Kinase inhibitors such as BGB 3245, which treats advanced solid tumors with BRAF mutations.

Data about vendors have been covered in this report. Download the Sample Report

Key Benefits for Industry Players & Stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Expand operations in the future - To get requisite details, ask for a custom report.

Market Segmentation:

The report extensively covers the BRAF kinase inhibitors market by the following demographic segmentation by product (dabrafenib, sorafenib, vemurafenib, and encorafenib), and geography (North America, Asia, Europe, and the Rest of the World (ROW).

• The market share growth by the dabrafenib segment will be significant for the market growth during the forecast period. Dabrafenib regulates cell growth by inhibiting the BRAF enzyme that is associated with the condition. During the forecast period, this market is anticipated to expand at a faster rate due to the high prevalence of thyroid and lung cancer. For instance, the US had approximately 2,36,820 people with lung and bronchus cancer in 2021, as reported by the National Institutes of Health (NIH).

Get a holistic overview of the market segments from industry experts to evaluate and
develop growth strategies. Download the Sample

Market Dynamics:

Key Drivers:

• One of the factors fueling the global BRAF kinase inhibitors industry growth is the high target affinity and specificity of BRAF kinase inhibitors.
• The majority of treatments are bad, which makes it harder for patients to stick with them. For instance, chemotherapy is the current standard of care (SOC) and is known to target rapidly dividing cells.
• However, it's possible that chemotherapy drugs slow down the activity of bone marrow, the lining of the mouth and intestines, and hair follicles, which normally divide quickly.
• As a result, BRAF kinase inhibitors with demonstrated efficacy in oncology applications are being developed as a suitable treatment option for cancer through extensive research.
• The most anticipated small molecule targeted therapy for the treatment of carcinomas is BRAF kinase inhibitors.

Major Trends:

• Expansion of research areas is one of the primary BRAF kinase inhibitors market trends that is expected to impact the industry positively in the forecast period. 
• NSCLC, melanomas, and RCC are just a few of the oncology conditions for which these inhibitors are effective. As a result, a number of vendors are trying to make these drugs more clinically available. There are currently four approved BRAF kinase inhibitors.
• However, companies are investigating the use of BRAF kinase inhibitors to treat more than three distinct types of cancer because of their high target affinity and specificity.
• Similarly, approximately fifty clinical trials for various cancers are being conducted by various businesses.
• During the forecast period, these factors will also help the market grow.

Key Challenges:

• A primary challenge impeding the global BRAF kinase inhibitors industry growth is the availability of substitute therapies such as radiation therapy and laser therapy, along with therapeutic options such as chemotherapies. 
• In addition, the market is witnessing a shift toward biological treatments. Alternative treatments have outperformed the available BRAF kinase inhibitors.
• In addition, biological medicines have few to no side effects, making them an even better option for treating carcinomas.
• As a result, the preference for alternative treatments may hinder the global BRAF kinase inhibitors market's expansion during the forecast period.

To get detailed insights about inclusions and exclusions, buy the report  

What are the key data covered in this BRAF Kinase Inhibitors Market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the BRAF kinase inhibitors market between 2022 and 2026
• Precise estimation of the size of the BRAF kinase inhibitors market and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the BRAF kinase inhibitors market across North America, Asia, Europe, and the Rest of the World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of BRAF Kinase inhibitors market vendors

Gain instant access to 17,000+ market research reports. 
Technavio's SUBSCRIPTION platform

Related Reports:

• The beta-lactam and beta-lactamase inhibitors market size is expected to increase by USD 9.04 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.44%. The report extensively covers beta-lactam and beta-lactamase inhibitors market segmentation by route of administration (oral, intravenous, and others) and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The special regulatory designations are notably driving the beta-lactam and beta-lactamase inhibitors market growth. 
• The PD-1 and PD-L1 inhibitors market size is expected to increase by USD 49.34 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 19.31%. The report extensively covers PD-1 and PD-L1 inhibitors market segmentation by application (solid tumors and blood-related tumors) and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The increasing prevalence of cancer is notably driving the PD-1 and PD-L1 inhibitors market growth.

Browse for Technavio's Health Care Market Reports            

Table of contents 

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product

• 5.1 Market segments
• Exhibit 24: Chart on Product - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Product - Market share 2021-2026 (%)

• 5.2 Comparison by Product
• Exhibit 26: Chart on Comparison by Product
• Exhibit 27: Data Table on Comparison by Product

• 5.3 Dabrafenib - Market size and forecast 2021-2026
• Exhibit 28: Chart on Dabrafenib - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Dabrafenib - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Dabrafenib - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Dabrafenib - Year-over-year growth 2021-2026 (%)

• 5.4 Sorafenib - Market size and forecast 2021-2026
• Exhibit 32: Chart on Sorafenib - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Sorafenib - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Sorafenib - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Sorafenib - Year-over-year growth 2021-2026 (%)

• 5.5 Vemurafenib - Market size and forecast 2021-2026
• Exhibit 36: Chart on Vemurafenib - Market size and forecast 2021-2026 ($ million)
• Exhibit 37: Data Table on Vemurafenib - Market size and forecast 2021-2026 ($ million)
• Exhibit 38: Chart on Vemurafenib - Year-over-year growth 2021-2026 (%)
• Exhibit 39: Data Table on Vemurafenib - Year-over-year growth 2021-2026 (%)

• 5.6 Encorafenib - Market size and forecast 2021-2026
• Exhibit 40: Chart on Encorafenib - Market size and forecast 2021-2026 ($ million)
• Exhibit 41: Data Table on Encorafenib - Market size and forecast 2021-2026 ($ million)
• Exhibit 42: Chart on Encorafenib - Year-over-year growth 2021-2026 (%)
• Exhibit 43: Data Table on Encorafenib - Year-over-year growth 2021-2026 (%)

• 5.7 Market opportunity by Product
• Exhibit 44: Market opportunity by Product ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview
• Exhibit 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation
• Exhibit 46: Chart on Market share by geography 2021-2026 (%)
• Exhibit 47: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison
• Exhibit 48: Chart on Geographic comparison
• Exhibit 49: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Asia - Market size and forecast 2021-2026
• Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.5 Europe - Market size and forecast 2021-2026
• Exhibit 58: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 62: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 66: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 China - Market size and forecast 2021-2026
• Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.9 India - Market size and forecast 2021-2026
• Exhibit 74: Chart on India - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on India - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on India - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on India - Year-over-year growth 2021-2026 (%)

• 7.10 Denmark - Market size and forecast 2021-2026
• Exhibit 78: Chart on Denmark - Market size and forecast 2021-2026 ($ million)
• Exhibit 79: Data Table on Denmark - Market size and forecast 2021-2026 ($ million)
• Exhibit 80: Chart on Denmark - Year-over-year growth 2021-2026 (%)
• Exhibit 81: Data Table on Denmark - Year-over-year growth 2021-2026 (%)

• 7.11 Canada - Market size and forecast 2021-2026
• Exhibit 82: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 83: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 84: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 85: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography
• Exhibit 86: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges
• Exhibit 87: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
• Exhibit 88: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption
• Exhibit 89: Overview on factors of disruption

• 9.4 Industry risks
• Exhibit 90: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 91: Vendors covered

• 10.2 Market positioning of vendors
• Exhibit 92: Matrix on vendor position and classification

• 10.3 Asana BioSciences LLC
• Exhibit 93: Asana BioSciences LLC - Overview
• Exhibit 94: Asana BioSciences LLC - Product / Service
• Exhibit 95: Asana BioSciences LLC - Key offerings

• 10.4 Bayer AG
• Exhibit 96: Bayer AG - Overview
• Exhibit 97: Bayer AG - Business segments
• Exhibit 98: Bayer AG - Key offerings
• Exhibit 99: Bayer AG - Segment focus

• 10.5 BeiGene Ltd.
• Exhibit 100: BeiGene Ltd. - Overview
• Exhibit 101: BeiGene Ltd. - Business segments
• Exhibit 102: BeiGene Ltd. - Key offerings
• Exhibit 103: BeiGene Ltd. - Segment focus

• 10.6 F. Hoffmann La Roche Ltd.
• Exhibit 104: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 105: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 106: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 107: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 108: F. Hoffmann La Roche Ltd. - Segment focus

• 10.7 Novartis AG
• Exhibit 109: Novartis AG - Overview
• Exhibit 110: Novartis AG - Business segments
• Exhibit 111: Novartis AG - Key offerings
• Exhibit 112: Novartis AG - Segment focus

• 10.8 Ono Pharmaceutical Co. Ltd.
• Exhibit 113: Ono Pharmaceutical Co. Ltd. - Overview
• Exhibit 114: Ono Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 115: Ono Pharmaceutical Co. Ltd. - Key offerings

• 10.9 Pfizer Inc.
• Exhibit 116: Pfizer Inc. - Overview
• Exhibit 117: Pfizer Inc. - Product / Service
• Exhibit 118: Pfizer Inc. - Key news
• Exhibit 119: Pfizer Inc. - Key offerings

• 10.10 Pierre Fabre SA
• Exhibit 120: Pierre Fabre SA - Overview
• Exhibit 121: Pierre Fabre SA - Business segments
• Exhibit 122: Pierre Fabre SA - Key offerings
• Exhibit 123: Pierre Fabre SA - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist
• Exhibit 124: Inclusions checklist
• Exhibit 125: Exclusions checklist

• 11.3 Currency conversion rates for US$
• Exhibit 126: Currency conversion rates for US$

• 11.4 Research methodology
• Exhibit 127: Research methodology
• Exhibit 128: Validation techniques employed for market sizing
• Exhibit 129: Information sources

• 11.5 List of abbreviations
• Exhibit 130: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio